Delivery Order SPE2DB20D3101-SPE2DB25FRLU2
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Xcopri 50 mg tablets (30-count) with a ceiling value of $1,182.13. This firm fixed-price delivery order, set to complete by August 1, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The contract involves no set-aside designation, indicating it was competitively awarded through open competition....
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Xcopri 25 mg tablets in a 30-count package. This firm fixed price delivery order, valued at $1,769.31, represents a non-set-aside competitive award with an ultimate completion date of September 4, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is executed...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Xcopri 50 mg tablets (30-count) with a ceiling value of $2,070.10. This competitive award utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The contract carries no set-aside designation, indicating it...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,413.60 on August 25, 2025, for the supply of Xcopri 200 mg tablets (30-count). The contract is classified as a firm fixed price delivery order with an ultimate completion date of August 26, 2025, and represents a non-competitive set-aside award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is the place of performance for this order. This delivery order is issued under the company's...
- The Defense Logistics Agency awarded a $2,830.02 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Xcopri 200 mg tablets (30-count). The contract, which is set to complete by August 20, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Xcopri 100 mg tablets in quantities of 30 units, with a ceiling value of $2,357.92 and an ultimate completion date of August 11, 2025. This competitively awarded, non-set-aside contract utilized firm fixed price pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Xcopri 100 mg tablets (30-count packaging) valued at $1,037.97. This firm fixed-price delivery order, with an ultimate completion date of August 18, 2025, represents a competitively awarded contract with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $3,536.88 delivery order to AmerisourceBergen Drug Corp on May 13, 2025, for the supply of Xcopri 100 mg tablets (30-count units). This firm fixed-price, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical product will be delivered to the company's corporate office location in...
- The Defense Logistics Agency awarded a $2,357.92 delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Xcopri 25 mg tablets (30-count). This competitively awarded, firm fixed-price contract carries an ultimate completion date of August 6, 2025, and represents a child order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The contract involves no set-aside designation and identifies Conshohocken, Pennsylvania, as the place of performance,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Xcopri 200 mg tablets (30-count units) on May 20, 2025, with an ultimate completion date of May 21, 2025. This firm fixed-price delivery order, valued at $1,768.44, represents a non-set-aside competitive award and will be performed at the contractor's Conshohocken, Pennsylvania facility. The contract is issued as a child order under AmerisourceBergen's larger pharmaceutical supply vehicle...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRLU2Delivery Order
The Defense Logistics Agency awarded a $4,857.44 delivery order to AmerisourceBergen Drug Corp on May 30, 2025, for the supply of Xcopri 50 mg tablets (30-count units). This firm fixed-price contract, with an ultimate completion date of June 2, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The contract was competitively awarded with no set-aside designation, and performance will be executed from the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, has established itself as a critical vendor for federal medical procurement through its comprehensive portfolio of brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities. As a prime contractor supporting military and veteran healthcare systems, the company leverages its global pharmaceutical support capabilities to deliver diverse therapeutic products across the Defense Health Agency and other government healthcare systems. This delivery order for Xcopri, a neurological treatment medication, reflects the company's ongoing role in fulfilling DLA's pharmaceutical supply requirements for federal medical programs worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.9k | 5/30/25 |